Break Up Big Medicine Act
- Bill Number
- S. 3822
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-02-10: Read twice and referred to the Committee on the Judiciary.
- Last Updated
- 2026-02-27T19:08:48Z
AI-Generated Summary
Purpose of the Legislation
The "Break Up Big Medicine Act" aims to address vertical integration in the U.S. healthcare system by prohibiting common ownership between certain upstream entities (like insurers and pharmacy benefit managers) and downstream providers (like physicians and pharmacies). It seeks to eliminate conflicts of interest that lead to anti-competitive practices, such as steering patients to affiliated services, inflating costs, and evading profit limits, ultimately restoring competition and protecting patients, physicians, pharmacies, and taxpayers.
Key Provisions
- Ownership Prohibitions:
- It is unlawful for any person or entity to simultaneously own, operate, or control:
- A "provider" (e.g., physicians, hospitals, pharmacies) or a "management services organization" (MSO; an entity that provides non-medical administrative services like billing or IT to providers) and both an insurance company and a pharmacy benefit manager (PBM; a company that negotiates drug prices, manages pharmacy networks, and handles prescription claims for health plans).
- A provider or MSO and a prescription drug or medical device wholesaler (a distributor of drugs or devices to other businesses, not directly to patients).
- Entities in violation must divest (sell off) one side of the ownership within 1 year of the law's enactment.
- Enforcement Mechanisms:
- The Federal Trade Commission (FTC) and the Department of Justice's (DOJ) Antitrust Division share jurisdiction to enforce the prohibitions.
- Non-compliance penalties include placing 10% of a company's monthly profits into escrow; if divestment fails by the deadline, funds go to a healthcare relief fund, and a court-appointed trustee can force the sale.
- Divestments must be reported to the FTC and DOJ for review under the Hart-Scott-Rodino Act (a law requiring pre-merger notifications for large deals), bypassing usual size thresholds, with the review period pausing the divestment timeline.
- The FTC and DOJ can block future deals that recreate these conflicts and must assess impacts on competition and public interest.
- Civil Actions and Remedies:
- Lawsuits can be filed by the HHS Inspector General, DOJ Antitrust Assistant Attorney General, FTC, or state attorneys general to enforce compliance.
- Private individuals harmed by violations can sue in state or federal court for treble damages (three times actual losses), attorney fees, and other relief like injunctions (court orders to stop actions).
- State attorneys general can sue on behalf of residents for damages.
- Courts can order divestitures, disgorgement (returning ill-gotten profits) to a FTC-managed fund for community healthcare needs, and other equitable remedies; jury trials are available upon request.
- Additional Requirements:
- The FTC must issue rules to implement the law and provide divestment guidance within 30 days.
- Quarterly reports on compliance and divestitures must be submitted to Congress.
- The law does not limit other existing enforcement powers and includes a severability clause (if one part is invalidated, the rest remains effective).
Significant Changes to Existing Law
- Introduces outright bans on specific vertical ownership structures in healthcare, going beyond current antitrust laws (like the Sherman or Clayton Acts) that address mergers or monopolies reactively through case-by-case reviews.
- Expands enforcement by granting new joint FTC-DOJ authority over structural separations (forced breakups) and mandatory pre- and post-divestment reviews without size limits.
- Creates a novel private right of action for individuals with enhanced remedies (e.g., treble damages), which is broader than typical antitrust private suits.
- Establishes a disgorgement fund for healthcare relief, a new tool not commonly tied to antitrust enforcement.
- Overrides certain thresholds in the Hart-Scott-Rodino Act for healthcare divestments, streamlining oversight.
Potential Impacts
- On Government Agencies: Increases workload and authority for the FTC, DOJ, and HHS to monitor, enforce, and review thousands of entities, potentially requiring more resources; creates a new fund for redistributing recovered profits to support community health needs.
- On Citizens: Patients may benefit from reduced drug and service costs due to less steering and more competition, but short-term disruptions from divestitures could affect access to care; individuals gain easier legal recourse for harms like overcharges.
- On International Relations: Minimal direct impact, as the law focuses on domestic commerce, though it could influence global healthcare firms operating in the U.S. by forcing restructurings.
- Broader effects include potential market fragmentation, encouraging independent providers and pharmacies, but risking temporary instability in supply chains for drugs and devices.
Main Stakeholders Affected
- Large Healthcare Conglomerates: Insurers (e.g., those employing 10% of physicians), PBMs (top three handle 80% of claims), wholesalers (top three control 98% of drug distribution), and vertically integrated firms face mandatory divestitures, potentially worth billions (e.g., recent $16 billion in acquisitions).
- Providers and Professionals: Physicians (over 75% now corporate-employed), hospitals, pharmacies, and MSOs may see ownership changes, gaining independence but losing integrated support.
- Patients and Consumers: Directly benefit from aimed reductions in costs and conflicts but could face service disruptions.
- Pharmacies and Taxpayers: Independent pharmacies may gain from fairer reimbursements; taxpayers save via prevented profit evasion in programs like Medicare Advantage.
- Government and Regulators: FTC, DOJ, state attorneys general, and HHS gain enforcement tools; Congress receives ongoing oversight reports.
- Smaller Entities: Independent doctors and pharmacies could thrive with restored competition.
Notable Legal, Constitutional, or Political Implications
- Legal: Relies on Congress's Commerce Clause authority (Article I, Section 8 of the Constitution) to regulate interstate healthcare activities, potentially facing challenges if courts view it as overreach into intrastate practices. Expands antitrust tools with structural remedies (e.g., forced divestitures), which are rare and could set precedents for other industries. The private right of action may lead to increased litigation, easing proof burdens compared to traditional antitrust cases.
- Constitutional: Affirms federal power over national conglomerates but includes severability to protect the law if parts are struck down; no direct First Amendment or due process issues noted, though divestiture timelines (1 year) could raise fairness concerns.
- Political: Bipartisan sponsorship (Sens. Warren and Hawley) signals cross-aisle concern over corporate consolidation; could reshape healthcare policy by prioritizing competition over integration, influencing future debates on drug pricing and insurer accountability without addressing root causes like patent laws.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2026-02-10: Read twice and referred to the Committee on the Judiciary.
- 2026-02-10: Introduced in Senate
Bill Versions
- Break Up Big Medicine Act — issued 2026-02-10 — PDF (19 pages)